Information Provided By: 
Fly News Breaks for February 11, 2020
BHVN
Feb 11, 2020 | 06:54 EDT
Mizuho analyst Vamil Divan lowered his price target for Biohaven Pharmaceutical to $58 from $62 and maintains a Buy rating on the shares. After speaking to management following the "disappointing" data readout for troriluzole in generalized anxiety disorder, the analyst has continued confidence in the rimegepant program in both acute migraine treatment and in migraine prevention. He sees "significant upside in the stock from here."
News For BHVN From the Last 2 Days
BHVN
Apr 25, 2024 | 10:38 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here
